DanCann Pharma Income Statement

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	8.22	7.15	7.19	2.31	-	-0.42
Revenue Growth (YoY)	3.55%	-0.50%	211.89%	-	-	-
Cost of Revenue	9.64	10.88	12.9	8.8	2.84	-
Gross Profit	-1.42	-3.72	-5.71	-6.49	-2.84	-0.42
Selling, General & Admin	7.95	9.45	8.52	7.12	2.94	0.2
Other Operating Expenses	-0.28	-0.28	-0.04	-	-	-
Operating Expenses	54.77	56.39	10.71	8.01	3.04	0.2
Operating Income	-56.19	-60.12	-16.42	-14.51	-5.87	-0.63
Interest Expense	-2.18	-2.33	-3.02	-1.26	-0.14	-0.01
Interest & Investment Income	-	0.2	1.19	0.58	0.02	-
Pretax Income	-58.38	-62.24	-18.25	-15.19	-5.99	-0.64
Income Tax Expense	0.73	0.02	-2.19	-3.44	-1.73	-0.14
Net Income	-59.11	-62.26	-16.06	-11.75	-4.26	-0.5
Net Income to Common	-59.11	-62.26	-16.06	-11.75	-4.26	-0.5
Shares Outstanding (Basic)	704	142	65	23	9	-
Shares Outstanding (Diluted)	704	142	65	23	9	-
Shares Change (YoY)	750.98%	117.84%	187.72%	154.96%	-	-
EPS (Basic)	-0.08	-0.44	-0.25	-0.52	-0.48	-
EPS (Diluted)	-0.08	-0.44	-0.25	-0.52	-0.48	-
Free Cash Flow	-13.57	-12.04	-12.74	-18.36	-11.68	-0.32
Free Cash Flow Per Share	-0.02	-0.09	-0.20	-0.81	-1.32	-
Gross Margin	-17.27%	-52.03%	-79.44%	-281.74%	-	-
Operating Margin	-683.60%	-840.42%	-228.38%	-629.41%	-	-
Profit Margin	-719.11%	-870.40%	-223.45%	-509.76%	-	-
Free Cash Flow Margin	-165.09%	-168.33%	-177.16%	-796.31%	-	-
EBITDA	-52.93	-56.74	-14.19	-13.62	-5.78	-0.62
EBITDA Margin	-	-	-197.34%	-	-	-
D&A For EBITDA	3.26	3.38	2.23	0.89	0.09	0.01
EBIT	-56.19	-60.12	-16.42	-14.51	-5.87	-0.63
EBIT Margin	-	-	-228.38%	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.